8-K: Beyond Air Appeals Nasdaq Delisting Notice

Beyond Air has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting notice regarding its failure to maintain a $1.00 minimum bid price.

Summary

• Beyond Air received a notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement.
• The company has formally requested a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
• The hearing request stays any immediate suspension or delisting of the company's common stock.
• The hearing is scheduled for May 14, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the threat of delisting indicates significant downward pressure on the stock price and potential future financing difficulties.

Positives

• The company has taken immediate procedural action to stay the delisting process.
• The common stock remains listed on Nasdaq pending the outcome of the hearing.

Negatives

• The company is currently in violation of Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price.
• There is no guarantee that the Nasdaq Hearings Panel will grant the request for continued listing.
• The company faces the risk of delisting if it cannot regain compliance with listing standards.

Risks

• Potential delisting from the Nasdaq Stock Market if the appeal is unsuccessful.
• Inability to regain compliance with the $1.00 minimum bid price requirement within the timeframe granted by the Panel.
• Negative impact on stock liquidity and investor confidence due to the delisting threat.

Future Outlook

The company intends to present its case to the Nasdaq Hearings Panel to maintain its listing, though it acknowledges there is no assurance of a favorable outcome or that it will be able to regain compliance with listing requirements.

Management Comments

• The company has timely requested a hearing to appeal the Staff's determination.
• There can be no assurance that the Panel will grant the company's request for continued listing.

Industry Context

StockSavvy.ai notes that small-cap biotech and medical device companies frequently face Nasdaq compliance challenges during periods of market volatility or capital constraints, often requiring reverse stock splits or significant operational milestones to restore share price.

Comparison to Industry Standards

• Nasdaq listing compliance is a standard regulatory hurdle for small-cap equities.
• The appeal process is a common procedural step for companies attempting to avoid the transition to OTC markets.

Legal Proceedings

• The company is currently engaged in a regulatory appeal process with the Nasdaq Hearings Panel regarding listing compliance.

Stakeholder Impact

• Shareholders face uncertainty regarding the future liquidity and exchange listing of their holdings.
• The company may face increased scrutiny from creditors and potential investors.

Next Steps

• Attend the scheduled Nasdaq Hearings Panel meeting on May 14, 2026.
• Await the written decision from the Panel regarding the continued listing status.

Key Dates

Recommendation

Investors should maintain a hold position until the outcome of the Nasdaq hearing is determined, as the risk of delisting creates significant volatility and uncertainty regarding the company's capital market access.

Keywords

Beyond Air, XAIR, Nasdaq, Delisting, Compliance, Bid Price, Hearings Panel